Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zigakibart open-label multicenter biomarker study in adults with IgA nephropathy
jRCT2071250126Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Open-label, single-arm trial of zigakibart in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Change in mesangial IgA deposition. Started May 2026; status: recruiting.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2071250126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250126.